Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
ACTH 4-10 (Org 2766)
Cognitive & neuro
Evidence level
Limited evidence
Approval status
Investigational
Mechanism of action
- 1.Acts on melanocortin-4 receptors in the brain, which influence attention and motivation.
- 2.Facilitates nerve sprouting and regeneration in animal models.
- 3.Does not stimulate the adrenal cortex, so it avoids steroid effects.
- 4.Modulates dopamine-dependent behaviours in rodents.
- 5.Metabolised quickly unless chemically stabilised, as in Org 2766.
Studied for
- Chemotherapy-induced peripheral neuropathy
- Nerve regeneration after injury
- Cognitive decline in older adults
- Parkinson's disease and spinal cord injury
Reported effects
- Some small trials suggested faster nerve recovery
- Cognitive trials were negative or inconclusive
- No reliable clinical benefit established in any indication
Side effects
- Nausea
- Headache
- Skin darkening with larger doses
- No corticosteroid effects expected, unlike full ACTH
Research protocol
Research context only - an abandoned investigational drug. Trials used subcutaneous or intranasal doses in the microgram to milligram range for weeks to months, with nerve conduction studies or cognitive scales as endpoints. No approved protocol exists.
Research context only
Evidence justification
Several small controlled trials were run decades ago, but the results were negative or inconsistent and development was abandoned.